Do you want to read an article? Please log in or register.
Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland
Further Publications
Related content
Lung Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Lung Cancer
Vince M, Naqvi SMH, Pellini B, Verbosky M, Melzer D
doi: 10.1016/j.lungcan.2024.107999
RECOMMENDED
AsthmaFurther Publications
Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Park HS, Lee J, Kim H, Woo SD
doi: 10.1186/s12931-024-03084-7
RECOMMENDED
Lung Cancer
Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Okada M, Ohgino K, Horiuchi K, Sayama K, Arai D, Watase M, Kobayashi K, Terashima T, Ishioka K, Miyawaki M, Sakamaki F, Masuzawa K, Terai H, Yasuda H, Soejima K, Fukunaga K
doi: 10.3390/jcm13247815
Pulmonary Fibrosis
Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Adv Ther
Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, Ikeda R, Ochiai K, Sugiyama Y, Nukiwa T
doi: 10.1007/s12325-024-03079-2
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
RECOMMENDED
Asthma
A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Sci Rep
Song Y, Wang Z, Wang N, Xie X, Zhu T, Wang Y
doi: 10.1038/s41598-025-91463-5
RECOMMENDED
Pulmonary Fibrosis
Real-World Clinical Effectiveness and Safety of Antifibrotics in Progressive Pulmonary Fibrosis Associated with Rheumatoid Arthritis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Narváez J, Aguilar-Coll M, Vicens-Zygmunt V, Alegre JJ, Bermudo G, Molina-Molina M
doi: 10.3390/jcm13237074
COMMENTED
Cough
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet
Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, Maspero J, Fujieda S, Zhang L, Sousa AR, Woods SJ, Davis AM, Schalkwijk S, Edwards D, Ranganathan P, Follows R, Marshall C, Han JK, ANCHOR-1 and ANCHOR-2 trial investigators
doi: 10.1016/S0140-6736(25)00197-7